Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

IL23 Produced by MDSCs Promotes Castration-Resistant Prostate Cancer

DOI: 10.1158/2159-8290.CD-RW2018-115 Published August 2018
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: In patients with CRPC an increase in tumor-infiltrating MDSCs that secrete IL23 upregulates AR.

  • Mechanism: MDSC-derived IL23 activates STAT3–RORγ signaling to drive AR transcription and castration resistance.

  • Impact: IL23 blockade may resensitize CRPC to androgen-deprivation therapy and synergize with standard therapies.

Many patients with prostate cancer develop resistance to androgen-deprivation therapy and progress to an aggressive castration-resistant prostate cancer (CRPC). These patients have a poor prognosis and often have activation of androgen receptor (AR) signaling via alternative pathways, but the mechanisms underlying castration resistance remain poorly understood. Calcinotto and colleagues sought to understand the role of the tumor microenvironment in CRPC progression. Analysis of biopsies from patients with CRPC compared with castration-sensitive prostate cancer (CSPC) revealed that CRPCs had an enrichment of poly-morphonuclear myeloid-derived suppressor cells (PMN-MDSC). In mouse models of CRPC, PMN-MDSC infiltration was linked to AR activation, and thereby conferred castration resistance. Treatment with a CXCR2 antagonist reduced PMN-MDSC infiltration and delayed the progression to CRPC. Tumor-infiltrating MDSCs secreted IL23, which induced transcription of AR target genes, conferred resistance to androgen deprivation and promoted prostate cancer cell proliferation and survival. Accordingly, IL23 was expressed in PMN-MDSCs from biopsies from patients with CRPC, plasma IL23 levels were higher in patients with CRPC than patients with CSPC, and patients with CRPC had elevated mRNA levels of IL23A and IL23R. Mechanistically, IL23 released by MDSCs into the tumor microenvironment activated phoshpo-STAT3–RORγ signaling to drive AR transcription. Consistent with these findings, targeting IL23 with antibody blockade reversed castration resistance in a mouse model of prostate cancer, conferring sensitivity to the AR antagonist enzalutamide and reducing tumor growth. In addition to elucidating a mechanism by which MDSCs in the tumor microenvironment can promote CRPC, these findings suggest the potential for therapeutic targeting of IL23 to restore sensitivity to androgen deprivation in patients with CRPC.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 2018 Jun 27 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 8 (8)
August 2018
Volume 8, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IL23 Produced by MDSCs Promotes Castration-Resistant Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IL23 Produced by MDSCs Promotes Castration-Resistant Prostate Cancer
Cancer Discov August 1 2018 (8) (8) 912; DOI: 10.1158/2159-8290.CD-RW2018-115

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IL23 Produced by MDSCs Promotes Castration-Resistant Prostate Cancer
Cancer Discov August 1 2018 (8) (8) 912; DOI: 10.1158/2159-8290.CD-RW2018-115
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Prostate Cancer

  • Developmental Programs Are Reactivated in Prostate Cancer Metastasis
  • Remaining Prostate Luminal Cells Regenerate after Androgen Deprivation
  • DDR-Defective Metastatic Prostate Cancers Are Susceptible to Olaparib
Show more Prostate Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement